Delving into the Latest Updates on Autologous memory lymphocyte(Newish Technology (Beijing) Co., Ltd.) with Synapse

Overview

Basic Info

Drug Type

TCR therapy

Synonyms-

Target-

Mechanism

Gene transference, T lymphocyte replacements

Therapeutic Areas

NeoplasmsDigestive System Disorders

Active Indication

Hepatocellular Carcinoma

Inactive Indication-

Originator Organization

Novi Technology Beijing Co Ltd.Startup

Active Organization

Novi Technology Beijing Co Ltd.Startup

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：采用剂量递增设计评估原发性肝细胞癌根治术后高复发风险患者接受NewishT治疗的安全性和耐受性，确定II期临床研究推荐剂量。次要目的：评估总体安全性；初步探索原发性肝细胞癌根治术后高复发风险患者接受NewishT治疗的疗效。

[Translation]

Primary objective: To evaluate the safety and tolerability of NewishT in patients with a high risk of recurrence after radical surgery for primary hepatocellular carcinoma using a dose-escalation design, and to determine the recommended dose for Phase II clinical studies. Secondary objective: To evaluate overall safety; to preliminarily explore the efficacy of NewishT in patients with a high risk of recurrence after radical surgery for primary hepatocellular carcinoma.

Start Date26 Jul 2022

Sponsor / Collaborator

Novi Technology Beijing Co Ltd.Startup

100 Clinical Results associated with Autologous memory lymphocyte(Newish Technology (Beijing) Co., Ltd.)

Login to view more data

100 Translational Medicine associated with Autologous memory lymphocyte(Newish Technology (Beijing) Co., Ltd.)

Login to view more data

100 Patents (Medical) associated with Autologous memory lymphocyte(Newish Technology (Beijing) Co., Ltd.)

Login to view more data

100 Deals associated with Autologous memory lymphocyte(Newish Technology (Beijing) Co., Ltd.)

Login to view more data